Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market. Amgen sells RANKL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback